首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1140752

轉染試劑和儀器的全球市場-2022-2029

Global Transfection Reagents and Equipment Market - 2022-2029

出版日期: 2022年10月20日 | 出版商:

DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

癌症發病率上升推動市場增長

癌症發病率上升是推動全球轉染試劑和設備市場的主要因素之一。例如，根據世衛組織的數據，癌症是全球死亡的主要原因，2020 年全球約有 1000 萬人死於癌症。大約三分之一的癌症死亡是由吸煙、高體重指數、飲酒、水果和蔬菜攝入量低以及缺乏身體活動引起的。因此，癌症發病率的增加正在推動市場。

就發病率和死亡率而言，傳染病也是一個主要的全球健康問題。傳染病是環境、致病和宿主遺傳因素的複雜組合，它們在決定對微生物的易感性和感染過程中都發揮著作用。此外，在急診科就診後出院時的主要診斷是傳染病或寄生蟲病的病例越來越多。這樣一來，傳染病暴發的數量在上升，帶動了市場。

此外，近期生物製藥行業的專利懸崖更加明顯，一些重磅生物藥專利即將到期。因此，一些公司已開始投資製造生物仿製藥以替代非專利生物製劑，以克服收益遞減的威脅。因此，專利到期的威脅刺激了轉染技術的採用率，帶來了巨大的市場收益。

然而，轉染試劑和裝置的高成本、試劑插入過程中的風險因素、轉染試劑的選擇性功效和一定的局限性以及轉染技術相關的細胞毒性是製約轉染試劑和裝置市場的主要因素。

此外，病毒載體隨機整合到基因組中，限制了可有效轉染的細胞數量，限制了其臨床和實驗室使用，並帶來顯著的生物危害風險，是試劑提供的約束的一部分。

地理滲透。

北美是預測期內的主要地區。

由於各種癌症發病率的上升、對蛋白質組學和基因組學技術的需求增加以及政府對預防醫學的積極舉措，北美在全球轉染試劑和設備市場上佔據主導地位。癌症發病率的上升預計將提振市場。例如，到 2021 年，美國將有 1,898,160 例新的癌症病例和 608,570 例癌症死亡。因此，越來越多的癌症患者正在推動市場。與預防性醫療保健相關的積極政府舉措的存在預計將提振市場。例如，美國癌症協會已投資超過 48 億美元用於癌症研究，以尋找更好的治療方法，了解導致癌症的原因，並改善癌症患者的生活質量。國家癌症研究所還開展和支持癌症預防、原因、診斷、治療、癌症康復、癌症患者護理連續性、健康信息傳播等項目的研究，並編制了《國家癌症計劃》。因此，政府對預防醫學的承諾正在推動市場。籌款和國家科學基金會 (NSF) 等聯邦機構為生物技術部門提供大量資金，以開展基於生物技術的研究。此外，預計 NIH 和研究信託基金等國際資助機構將通過為基因研究調查提供資金，在市場增長中發揮重要作用。

競爭格局。

在全球轉染試劑和設備市場上運營的主要公司有 Bio-Rad Laboratories, Inc、Merck KGaA、Agilent Technologies、Illumina, Inc、Norgen Biotek Corp、QIAGEN、PerkinElmer Inc、OriGene Technologies Inc、Promega Corporation、Thermo Fisher Scientific Inc。一些主要的關鍵參與者正在遵循合併和合作戰略來擴展他們的業務。例如，2022 年 5 月，Agilent宣布與 APC 就實時過程監控展開合作。通過此次收購，兩家公司將結合技術，為客戶提供獨特的工作流程，支持通過液相色譜進行自動化過程分析。這種合作將增強客戶服務和技術。2022 年 2 月，Agilent收購了由 Virtual Control 開發的領先人工智能 (AI) 技術，Virtual Control 是一家人工智能和機器學習軟件開發商，為實驗室測試創建創新的分析解決方案。此次收購是對數字技術的投資，旨在提高實驗室生產力。2021 年 8 月，全球 DNA 測序領域的領導者 Illumina 宣布收購 GRAIL，一家專注於早期檢測多種癌症的醫療保健公司，用於“加速患者獲得挽救生命的多種癌症早期檢測測試”。2022 年 8 月，Merck收購了 Mecaro 的化學品業務，Mecaro 是一家在韓國上市的半導體加熱塊和化學前體製造商。通過此次收購，默克將擴大其電子業務並進一步提高其區域和全球能力。此次收購包括超過 30 億歐元的投資。

這份關於全球轉染試劑和設備市場的報告提供了大約 61 個市場數據表、51 個數字和 170 頁的訪問權限。

Market Overview

Transfection Reagents and Equipment Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 7.45 % during the forecast period (2022-2029).

Transfection is a process that involves the production of genetically modified cells with the utilization of foreign nucleic acid (DNA and RNA). Transfection is essential equipment used in investigation studies for gene function and the modulation of gene expression. The transfection reagents and equipment market is driven by the rising incidence of infectious diseases, increase in the R&D expenditure and research activities by the pharmaceutical and biotechnology companies, technological advancements in transfection, increasing incidence of cancer, and the presence of various government initiatives.

Market Dynamics: Increasing incidence of cancer drive market growth.

The rising incidence of cancer is one of the dominating factors propelling the global transfection reagents and equipment market. For instance, According to WHO, cancer is the leading cause of death worldwide and is responsible for around 10 million deaths in 2020 globally. Around one-third of deaths from cancer are due to tobacco use, high body mass index, alcohol consumption, low fruit and vegetable intake, and lack of physical activity. Thus, the rising incidences of cancer are driving the market.

Also, infectious diseases represent a significant health problem worldwide in terms of morbidity and mortality. A complex combination of environmental, pathogen, and host genetic factors plays a role in determining both susceptibilities to microbes and the course of infection. Also, the number of emergency department visits resulting in hospital admission with a principal hospital discharge diagnosis of infectious and parasitic diseases increased. Thus, the rising incidence of infectious diseases is driving the market.

Further, in recent times, the biopharmaceutical industry has seen a significant patent cliff as several blockbuster biologics are facing patent expiration. Consequently, several companies have begun investing in producing biosimilar alternatives to off-patent biologics to overcome the threat of revenue loss. Hence, the patent cliff threat has significantly benefitted the market by spurring the adoption rate of transfection technology.

However, the high cost of transfection reagents and equipment, risk factors during insertion of the reagents, selective effectiveness and certain limitations of transfection reagents and cytotoxic effect associated with transfection technology are the major factors restraining the transfection reagents and equipment market.

The number of cells that the methods can effectively transfect, and the limited clinical and laboratory use, owing to the integration of viral vectors randomly into the genome producing significant bio-hazardous risks, are some of the limitations offered by the transfection reagents.

Market Segmentation: The reagent segment is projected to be the dominant segment in the market during the forecast period.

The reagents segment is sub-segmented into lipid-mediated transfection, DEAE-dextran, activated dendrimers, calcium phosphate, cationic polymers, and others. The reagents segment is expected to dominate the market over the forecast period. It is owing to the increasing commercial adoption rates of these reagents. For instance, OZ Biosciences revolutionized Polyfection with the design of Helix-IN, a novel patented Cationic Hydroxylated Amphiphilic Multi-block Polymer (CHAMP Technology). This novel bi-functional co-polymer is biocompatible, ionizable, pH-responsive, and biodegradable. Thus, the increased adoption of reagents owing to the presence of products is driving the market.

Transfection equipment can be sub-segmented into liposomes, electroporation, microinjection, laserfection, and others.

The equipment segment held a significant market share in the forecast period. The rapidly growing volume of genomics-based research and development initiatives and the introduction of user-friendly products like portable DNA sequencers are expected to propel the transfection reagent and equipment market during the forecast period. The presence of expensive laser-based equipment used for the different transfection methods like laserfection or optoinjection is estimated to drive the growth of the equipment segment.

The transfection reagents and equipment market can be segmented by application into biomedical research, protein production, and therapeutic delivery. Biomedical research is further sub-segmented into gene expression studies, cancer research, and transgenic models.

Biomedical research is expected to boost the market over the forecast period, owing to the increased adoption of reagents for biomedical research. For instance, AltoFect of Altogen biosystems transfection reagent enables the researchers to overcome the challenges and limitations of primary cells and difficult-to-transfect cell lines. Also, Gene expression studies were expected to be the most prominent application. The expansion of the genomic data pool and the growing emphasis on translating genomic information in the clinical workflow lead to a considerable share of this segment. The presence of a substantial number of ongoing research projects that aim at the in-depth investigation of key mechanisms, which underlie chromosomal anomalies, is also supplementing the growth of the segment.

Geographical Penetration: North America is the dominating region during the forecast period.

North America is dominating the global transfection reagents and equipment market owing to the rising incidence of various cancers, the increasing demand for proteomics and genomics technology, and the upfront initiatives taken by the government related to preventive healthcare. The rising incidence of cancer is expected to boost the market. For instance, in 2021, 1,898,160 new cancer cases and 608,570 cancer deaths will occur in the United States. Thus, the growing number of cancer cases is driving the market. The presence of upfront initiatives taken by the government related to preventive healthcare is expected to boost the market. For instance, the American cancer society has invested more than $4.8 billion in cancer research to find more and better treatments, uncover factors that may cause cancer, and improve cancer patients' quality of life. Also, the National Cancer Institute coordinated the National Cancer Program, which conducts and supports the research, health information dissemination, and other programs related to the prevention, cause, diagnosis, and treatment of cancer, rehabilitation from cancer, and continuous care of cancer patients. Thus, government initiatives for preventive healthcare are driving the market. Funding and federal agencies, like the National Science Foundation (NSF), offer the biotechnology sector huge funding to carry out biotechnology-based investigational studies. Moreover, international funding bodies like NIH and Welcome Trust are expected to play a vital role in the market growth by giving the funds for genetic research studies.

Competitive Landscape:

The key players operating in the global transfection reagents and equipment market are Bio-Rad Laboratories, Inc., Merck KGaA, Agilent Technologies, Illumina, Inc., Norgen Biotek Corp., QIAGEN, PerkinElmer Inc., OriGene Technologies Inc., Promega Corporation, and Thermo Fisher Scientific Inc. Some major key players follow merger and collaboration strategies to expand their business. For instance, in May 2022, Agilent announced a collaboration with APC on Real-Time Process Monitoring. Through this acquisition, both companies combined their technologies to provide unique workflows to customers that support automated process analysis via liquid chromatography. This collaboration strengthens services and technologies to the customers. In February 2022, Agilent acquired advanced artificial intelligence (AI) technology developed by Virtual Control, an AI and machine learning software developer that creates innovative analysis solutions in lab testing. This acquisition is an investment in digital technology to improve lab productivity. In August 2021, Illumina, the global leader in DNA sequencing, acquired GRAIL, a healthcare company focused on early life-saving detection of multiple cancers to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection tests. In August 2022, Merck acquired the Chemical Business of Mecaro, a Korea-based and publicly listed manufacturer of heater blocks and chemical precursors for semiconductors. Through this acquisition, Merk expands its Electronics business to further expand its regional capabilities and global capacity. This acquisition includes the investment of more than € 3 billion.

The global transfection reagents and equipment market report would provide an access to approximately 61 market data tables, 51 figures and 170 pages

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Product type
3.2. Market Snippet by Application
3.3. Market Snippet by End-user

4. Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The increasing incidences of cancer
  - 4.1.1.2. The presence of technological advancements in transfection
- 4.1.2. Restraints
  - 4.1.2.1. The limitations of transfection reagents
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Regulatory Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Unmet Needs

6. By Product type

6.1. Introduction
- 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
- 6.1.2. Market Attractiveness Index, By Product Type Segment
6.2. Reagents*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
  - 6.2.2.1. Lipid mediated transfection
  - 6.2.2.2. DEAE-dextran
  - 6.2.2.3. Calcium phosphate
  - 6.2.2.4. Activated dendrimers
  - 6.2.2.5. Cationic polymers
  - 6.2.2.6. Others
6.3. Equipment
- 6.3.1. Introduction
- 6.3.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
  - 6.3.2.1. Liposomes
  - 6.3.2.2. Electroporation
  - 6.3.2.3. Microinjection
  - 6.3.2.4. Laserfection
  - 6.3.2.5. Others

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application Segment
7.2. Biomedical research*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
- 7.2.3. Cancer research
- 7.2.4. Gene expression
- 7.2.5. Transgenic models
7.3. Protein production
7.4. Therapeutic delivery

8. By End-user

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
- 8.1.2. Market Attractiveness Index, By End-user Segment
8.2. Pharmaceutical and biotechnology companies *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
8.3. Research institutes
8.4. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
- 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
- 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. The U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
- 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
- 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. The U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Italy
  - 9.3.6.5. Spain
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
- 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
- 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
- 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
- 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. Australia
  - 9.5.6.5. Rest of Asia Pacific
9.6. The Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
- 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Bio-Rad Laboratories, Inc.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Key Highlights
- 11.1.4. Financial Overview
11.2. Merck KGaA
11.3. Agilent Technologies
11.4. Illumina, Inc.
11.5. Norgen Biotek Corp.
11.6. QIAGEN
11.7. PerkinElmer Inc.
11.8. OriGene Technologies Inc.
11.9. Promega Corporation
11.10. Thermo Fisher Scientific Inc. (LIST NOT EXHAUSTIVE)